Literature DB >> 30287877

Refocusing IBD Patient Management: Personalized, Proactive, and Patient-Centered Care.

Corey A Siegel1.   

Abstract

Medications are available that can be highly effective for the treatment of inflammatory bowel disease (IBD). However, there are multiple barriers in place to offer these treatments to the right patients at the right time. In addition to obstacles created by payers, there are concerns over medication side effects by patients and providers, and the logistic challenges of navigating the maze of initiating someone on biological therapy. As a gastroenterology community, we need to push the field forward for the sake of our patients. Current and future drug development for IBD is exciting, but we need to optimize what we have now to the best of our ability. When used appropriately and early enough in the disease course, our current medications can heal the bowel and prevent complications from developing. While recognizing that all patients do not need early intensive therapy, we need to identify the appropriate patients for more aggressive treatments. This article will describe how we can improve patient management now by shifting our focus to using a personalized, proactive, and patient-centered approach in our delivery of IBD care.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30287877     DOI: 10.1038/s41395-018-0246-x

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN: 0002-9270            Impact factor:   10.864


  6 in total

1.  Digital Health Technologies for Remote Monitoring and Management of Inflammatory Bowel Disease: A Systematic Review.

Authors:  Nghia H Nguyen; Ivonne Martinez; Ashish Atreja; Amy M Sitapati; William J Sandborn; Lucila Ohno-Machado; Siddharth Singh
Journal:  Am J Gastroenterol       Date:  2022-01-01       Impact factor: 10.864

Review 2.  Could Mucosal TNF Transcript as a Biomarker Candidate Help Optimize Anti-TNF Biological Therapy in Patients With Ulcerative Colitis?

Authors:  Guanglin Cui; Jon Florholmen; Rasmus Goll
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

3.  Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.

Authors:  Ryan C Ungaro; Berkeley N Limketkai; Camilla Bjørn Jensen; Clara Yzet; Kristine H Allin; Manasi Agrawal; Thomas Ullman; Johan Burisch; Tine Jess; Jean-Frederic Colombel
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-13       Impact factor: 11.382

4.  Drug therapy and monitoring for inflammatory bowel disease: a multinational questionnaire investigation in Asia.

Authors:  Chenwen Cai; Juntao Lu; Lijie Lai; Dongjuan Song; Jun Shen; Jinlu Tong; Qing Zheng; Kaichun Wu; Jiaming Qian; Zhihua Ran
Journal:  Intest Res       Date:  2022-04-29

5.  High Levels of Psychological Resilience Associated With Less Disease Activity, Better Quality of Life, and Fewer Surgeries in Inflammatory Bowel Disease.

Authors:  Priya Sehgal; Ryan C Ungaro; Carol Foltz; Brian Iacoviello; Marla C Dubinsky; Laurie Keefer
Journal:  Inflamm Bowel Dis       Date:  2021-05-17       Impact factor: 5.325

6.  Discovery and validation of mucosal TNF expression combined with histological score - a biomarker for personalized treatment in ulcerative colitis.

Authors:  Jon R Florholmen; Kay-Martin Johnsen; Renate Meyer; Trine Olsen; Øystein K Moe; Petter Tandberg; Mona D Gundersen; Jan-Magnus Kvamme; Knut Johnsen; Terje Løitegård; Gabriele Raschpichler; Cecilia Vold; Sveinung W Sørbye; Rasmus Goll
Journal:  BMC Gastroenterol       Date:  2020-10-02       Impact factor: 3.067

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.